

Date: September 08, 2026

To
BSE Limited ('BSE')
Listing Department
Corporate Relationship Department
Phiroze Jeejeebhoy Towers,
2nd Floor, Dalal Street,
Mumbai – 400 001
BSE Script Code: 544866

To
National Stock Exchange of India Ltd
Exchange Plaza,
Bandra-Kurla Complex,
Bandra (E), Mumbai 400 051
Symbol: MOLBIO

Subject: Investor Presentation on the Unaudited Financial Results (Standalone & Consolidated) for the quarter ended June 30, 2026.

Dear Sir/Madam,

Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), please find enclosed herewith a copy of the Investor Presentation or Communication, in connection with the Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter ended June 30, 2026.

This presentation will also be available on the Company's website at www.molbiodiagnostics.com in compliance with Regulation 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

You are requested to kindly take the same on record.

Thanking You.
Yours Faithfully,

For Molbio Diagnostics Limited

Darshan Raghunath Karekar
Company Secretary & Compliance Officer
M. No: F13569
Place: Verna-Goa



Innovation Led Diagnostic Products Company

Investor Presentation
Sept'2026



*This presentation and the accompanying slides (the "Presentation"), which has been prepared by **Molbio Diagnostics Ltd.** (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company shall be made except by means of a statutory offering document containing detailed information about the Company.*

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Stakeholders are advised to compare the data provided in the presentation with the full financial results available on the website of the Company as well as on the website of the NSE and BSE.

Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

“

"FY27 is a milestone year for Molbio, marking our transition to a listed company. I would like to thank our shareholders, employees, customers and partners for the trust they have placed in Molbio through our recent listing, and we remain committed to delivering on that trust through consistent execution. I am pleased to report that we have begun the year on a strong note, with healthy growth across both revenue and profitability in Q1. However, our business continues to have a non-linear revenue profile, with performance varying across quarters. We therefore believe it is important to assess our performance on a full-year basis. During the quarter, certain export orders pertaining to Q4 FY26, amounting to approximately ₹57 crore, were deferred due to the prevailing situation in the Gulf and were subsequently recognized in Q1 FY27. Total Income for Q1 FY27 stood at ₹411.48 Cr, with EBITDA at ₹103.68 Cr against a loss of ₹14.50 Cr in Q1 FY26. Growth continues to be led by test-kit consumption across the 12,500+ Truenat® devices sold in 90+ countries.

We entered FY27 with meaningful capacity headroom - FY26 device and test-kit utilization at 42% and 58%, respectively, positioning us for volume-led scale-up without near-term incremental capex. Our pipeline of 34 additional assays across 22 diseases remains on track and will be a key long-term driver as we extend beyond infectious disease into oncology and other non-communicable areas.

Internationally, we are deepening our presence across Africa and Southeast Asia, entering Latin America, and progressing regulatory pathways in developed markets, including CE-IVDR for our CTNG Test.

Following our listing on August 17, 2026, deployment of the net issue proceeds is underway across capex for automation and building our R&D facility in Bengaluru. We remain focused on disciplined execution, sustained R&D intensity and improving cash flow quality as our international and acquired businesses scale."

”



Sriram Natarajan

Executive Director, and Chief
Executive Officer (CEO)



Company & Business Overview

1990-2004

2005-2018

Sriram Natrajan, co-founded, Tulip Diagnostics Private Limited which later became one of the **largest in-vitro diagnostics reagent company in India**

Bigtec shifts its focus towards **chip-based PCR⁽¹⁾** research

Joint Venture between Molbio and Bigtec Innovations Private Limited and Bigtec Private Limited

Sriram Natarajan **exited Tulip Diagnostics Private Limited** pursuant to sale to PerkinElmer

2000

2009

2013

2018

1990

2005

2011

2017

Incorporation of Molbio Diagnostics along with its R&D arm Bigtec Labs

Bigtec creates a **'lab-on-a-chip'** model


Launch of the **semi-automatic PCR⁽¹⁾** device **'Truelab Uno'**

Fully- automatic PCR⁽¹⁾ device **"Truelab Uno"** approved by ICMR⁽²⁾

Journey Post Commercial Launch of Truenat Platform

2019-2022

2023 onwards



Note: (1) For an initial diagnosis of TB (Tuberculosis) and rifampicin resistance detection using molecular diagnostic technology (Source: Report titled "Molecular Diagnostics Industry Report" dated August 22, 2025 ("1Lattice Report")) (5) World Health Organisation. (2) Investment through its funds. (3) Investment through its indirect wholly owned subsidiary. (4) Indian Council of Medical Research. (5) Prognosys Medical Systems Private Limited

Innovation-led diagnostics company delivering accessible, accurate and affordable molecular testing

Broad & Growing Test Menu

43

Assays

30

Diseases Covered

Across infectious diseases, women's health, oncology & more

Global Scale & Adoption

12,500+

Truenat® Devices Installed

90+

Countries with Truenat® t Presence

17.6 Mn

Test Kits Sold in FY26

Recurring Business Model

73.98%

Product Revenue from
Test Kits in FY26

₹ 1,455 Cr

Total Income in FY26

Proprietary Technology

Truenat®

Portable | Battery-operated
Real-time PCR Platform

Rapid • Accurate • Easy to Use

Robust Innovation Engine

153

R&D Professionals
(136 Scientists)

207

Registered Patents

Strong In-house
R&D Capabilities
Across Platform, Assays &
Chemistry

WHO / ICMR / FIND
Endorsed Platform
for TB Diagnosis &
Rifampicin Resistance

Multiple Regulatory
Approvals &
Clinical Validations

Financial Performance (FY26)

₹ 1,455 Cr

Total Income

₹ 328 Cr

EBITDA

22.6%

EBITDA Margin

₹ 164 Cr

PAT

11.3%

PAT Margin

Deep scientific capability translated into scalable products, protected IP and future growth

Proven Innovation Capability

From scientific insight to scalable impact

Multidisciplinary R&D spanning science, engineering, product development, evidence generation and scale-up.

13+ YEARS

R&D and translation behind Truenat[®]

153

R&D Professionals Including 136 scientists

207

Patents Granted in India and overseas

Built Across Disciplines

Biology • Chemistry • Software • Engineering

DSIR-recognised Bengaluru R&D facility


Innovation Beyond The Lab

Science → Product → Evidence → Scale → Impact



Investing More To Drive Future Growth

Annual R&D investment (₹ Cr)



₹87.5 Cr	46%	₹215.9 Cr
FY26 R&D spend	Increase vs FY24	Cumulative FY24–FY26

Global Healthcare Burden - The Problem Statement

A significant diagnostic access gap continues to delay timely diagnosis, treatment and better health outcomes

Diagnostics Are Critical, Yet Underpenetrated



70%

Healthcare decisions depend on diagnostic information



Only **3-5%**

Healthcare budgets are allocated to diagnostic services



~3.6 Bn

People (47% of the global population) have limited or no access to diagnostics



81%

People in low-and lower-middle income countries lack access

- Diagnostic access is concentrated in urban and centralized laboratories
- Geographic distance, inadequate infrastructure and shortage of skilled professionals create major barriers
- Limited access leads to delayed diagnosis and sub-optimal outcomes

High Disease Burden Continues To Impact Global Health



10.7 Mn

people fell ill with TB in 2024



1.23 Mn

people died from TB in 2024



~2 in 5

people with drug-resistant TB accessed treatment

TB remains the world's leading cause of death from a single infectious agent.



Antimicrobial Resistance (Amr) - A Growing Concern

- Rising AMR increases the need for accurate pathogen identification and resistance detection
- Limited diagnostic capacity restricts appropriate treatment and drives inappropriate antibiotic use
- Stronger diagnostics is essential for AMR surveillance and stewardship



Infectious Diseases - A Persistent Burden

- Early detection and accurate diagnosis are critical for better patient outcomes
- Diagnostic gaps weaken disease surveillance and outbreak preparedness
- High burden in emerging and resource-limited settings

Emerging Need Decentralized / Point-of-care Diagnostics



Test at or near
the patient



Minimal
infrastructure



Faster
Results



Earlier
clinical
decision



Greater
reach &
impact



Traditional Model Centralized Laboratory Diagnostics



Sample
collected at
patient site



Sample
transported to
central lab



Infrastructur
e dependent



Specialist
workforce



Longer
turnaround time
(hours-days)

Bridging the diagnostic access gap with accurate, rapid and decentralised testing is essential to improve health outcomes, strengthen disease control and build more resilient healthcare systems.

The Truenat Platform - An Integrated Workflow

Device

UnoDx
(1 test)

Duo
(2 tests)

Quattro
(4 tests)



Key Platform Attributes



Portable
Lightweight and easy to transport



Fully Automatic
Minimal hands-on time and easy to use



Battery Operated
Works in areas with unreliable power



Point-of-care Ready
Designed for use at or near the patient



RAPID RESULTS
Sample to result in ~60 minutes[®]

Multi-disease Platform

43
ASSAYS

30
DISEASES


- **Disease-specific micro-PCR chips** operate on the same core platform
- Menu spans infectious and non-communicable diseases
- Includes **TB, Hepatitis B/C, HIV, HPV, COVID-19** and many more
- Platform designed to accommodate additional assays

- **TB**
- **Hepatitis**
- **HIV**
- **HPV**
- **COVID - 19**
- **Dengue**
- **Influenza & more**



Disease-specific Consumables

- Truenat® test kits are disease-specific, ready-to-use and single-use
- Micro-PCR chips contain pre-loaded PCR reagents for real-time PCR testing
- Designed for use exclusively with the Truenat® platform
- Expanding assay menu increases utility and potential utilization of the installed base

What Constitutes The Consumable




Strong Growth In Test-kit Consumption



Molbio has Presence across 30 Diseases in the Fast-Growing POCT Market for Infectious Diseases


Infectious Disease Testing Represents Significant Segment of Global POC(4) Market...

Global POC(4) Diagnostic Market Split by Therapy Area (\$b, CY25)




...With TB Tests Being the Leading Contributor

Global POC(4) Market Size for Infectious Diseases (\$b, CY25)



Significant Testing Market Across Diseases

POC(4) Tests Conducted (Million Tests, CY25)



✓ Indicates Molbio has existing commercialised tests

Point-of-Care Diagnostics Global TAM(2) of ~\$29.3b in CY25 Growing to ~\$67.1b in CY30 at 17.9% CAGR(1)

Note: All industry data is sourced from report titled "Molecular Diagnostics Industry Report" dated July 24, 2026 ("1Lattice Report") unless otherwise specified

(1) 2025-30P CAGR	(4) Point of care	(7) Human Papillomavirus	(10) Tuberculosis
(2) Total Addressable Market	(5) Gastrointestinal	(8) Hepatitis C virus	
(3) Point of care testing	(6) Sexually transmitted infection	(9) Hepatitis B	

Scaled, Multi-location Manufacturing Footprint

6 Manufacturing Facilities | 4 Locations


GOA 2 FACILITIES	Manufacturing of Truenat® Test Kits
VISAKHAPATNAM 1 FACILITY	Manufacturing of Truenat® Devices & Test Kit Components
BENGALURU 2 FACILITIES	Manufacturing of Test Kit Components & Radiology Devices
PUNE 1 FACILITY	Manufacturing of Digital Pathology Scanners

Geographically diversified facilities across key product categories ensure continuity, redundancy and scalability


Meaningful Installed Capacity With Headroom

TRUENAT® TEST KITS 39 Mn KITS / ANNUM	TRUENAT® DEVICES 5,400 DEVICES / ANNUM
---	--

FY26 UTILISATION



FY26 UTILISATION



Early investments in capacity provide headroom to support future growth in test kits and devices

Automation-enabled Manufacturing



Automation For Precision & Consistency

- Leveraging automation and advanced processes to improve precision, consistency and process efficiency



Integrated & Flexible Operations

- In-house manufacturing of core products
- EMS partners leveraged for Truenat® device assembly to meet demand efficiently



Scale With Quality

- Strong process control, validation and monitoring ensures consistent quality at scale

A flexible manufacturing architecture that combines in-house capabilities with outsourced assembly scalability

Integrated Quality Assurance & Quality Control



221 QA / QC PROFESSIONALS

- Dedicated QA-QC division at each manufacturing facility
- Rigorous testing of raw materials, in-process and finished products
- 100% quality control checks of test kits, reagents and cartridges before dispatch
- Quality systems spanning design, development, manufacturing, distribution and servicing



Design & Development



Manufacturing



Quality Control



Distribution



Servicing

International Quality Management Systems

ISO 13485:2016



Certified Quality Management System for Design, Development, Manufacturing, Distribution and servicing of:

- IVD reagents and kits
- Near-patient / POC IVD medical devices

Certified by TÜV SÜD Product Service GmbH

MDSAP




Quality Management System assessed against requirements of multiple regulatory jurisdictions:

BRAZIL

CANADA

USA

Regulatory & Product-level Validation



EU IVDR CLASS C

First Indian company to receive EU IVDR Class C Technical Documentation Assessment Certificate for Truenat® CT/NG






Prognosys Acquisition Unlocking Multiple Levers to Enhance Our Digital Radiology Capabilities



US FDA approved range of **digital imaging solutions** with a strong pipeline of **ultra portable devices** across various X-Ray Systems

End-to-End TB(1) Testing

PRORAD
X-Ray screening for TB⁽¹⁾



Truenat
RT-PCR⁽³⁾ confirmatory test for
TB⁽¹⁾

Note: All industry data is sourced from report titled "Molecular Diagnostics Industry Report" dated July 24, 2026 ("1Lattice Report") unless otherwise specified
(1) Tuberculosis
(2) Acquisitions
(3) Reverse transcription- Polymerase chain reaction



Investment in US based Company Furthering Global Reach and Diversifying Offerings

Whole Slide Scanner



OS-Six Scanner
(6 slides)



OS-Lite Brightfield
Scanner (15 slides)



OS-Ultra Brightfield
Scanner (80-480 slides)



OS-FiA Cytology
Scanner



OS-FS Frozen
Section Scanner



OS-FLi Fluorescence
Slide Scanner

Comprehensive Digital pathology Solutions

Provides digital pathology solutions, offering a range of digital pathology scanners, AI-powered analysis tools, and telepathology services, enabling remote consultations and collaboration

Wide Product Portfolio

Key products include OS 15 Scanner (scans 15 slides), OS Ultra Series (80, 160, 240, 320, 400 & 480) which scans in under 60 seconds without compromising image quality, and OS Lite, which is wirelessly-enabled for flexible storage, archiving, and management of digital images and metadata

Regulatory Milestones

Received US FDA 510(k) clearance (K260755) for its OptraScan System

Expand Our Geographical Presence across the Globe

Focus on enhancing exports, particularly to regions where we have presence, such as

Africa

Southeast Asia

Planning to enter markets with portfolio of Molbio products such as

EU

US

Develop New POC(1) Platforms for Other Communicable and Non-Communicable Diseases

Leverage R&D Capabilities to Develop New POC(1) Platforms Using Advanced Multiplex PCR(2) Technologies to Address Diagnostic Needs in:



Immunochemistry



Hematology

Communicable Diseases



Histopathology



Biochemistry

Non-Communicable Diseases



Antimicrobial Resistance

Expand Our Suite of Tests for Truenat®

34


Assays in Pipeline

22

Diseases in Pipeline

Key Tests Commercialized

- TB
- HPV(3)
- Hepatitis
- HIV(4)



Grow Inorganically Through Strategic Acquisitions and Alliances

Expertise in Strategic Acquisitions to Help Expand Capabilities...



...And Collaborations to Enhance Portfolio Offerings



Accelerating Innovation via EDGE Program



Establishing Centre of Excellence (CoE) at Bengaluru



Financials Performance - Quarter

Q1 FY27 Performance Highlight (Y-O-Y)

Total Income*

₹411.5 Cr

EBITDA*

₹103.7 Cr

EBITDA Margin

25.2%


PAT

₹52.7 Cr


PAT Margin

12.8%

Truenat® Devices Sold (Units)




Truenat® Test Kits Sold (Mn Units)




*Total Income & EBITDA includes other income

Profit & Loss Highlights – Quarterly


Total Income* (₹ Cr.)



EBITDA* (₹ Cr) & Margin %



Net Profit (₹ Cr) & Margin %



- **Q1 FY27 Total Income** stood at ₹411.5 Cr vs. ₹100.5 Cr in Q1 FY26, driven by higher Truenat® test-kit consumption
- **Q1 FY27 EBITDA** stood at ₹103.7 Cr vs. ₹(14.5) Cr, with EBITDA margin at **25.2% vs. (14.4%)**, reflecting operating leverage from higher test-kit volumes, partly offset by continued international go-to-market investments.
- **Q1 FY27 PAT** stood at ₹52.7 Cr vs. ₹(23.9) Cr, with PAT margin at **12.8%**.

Profit & Loss Statement – Quarterly

Particulars (₹ Cr)	Q1 FY27	Q1 FY26	Q4 FY26
Revenue from Operations	408.4	99.7	560.6
Other income	3.1	0.8	4.8
Total income	411.5	100.5	565.4
COGS	149.7	35.2	235.4
Employee Benefit Expenses	45.9	28.2	45.9
Other Expenses	112.2	51.6	120.6
EBITDA	103.7	(14.5)	163.5
EBITDA Margin %	25.2%	(14.4%)	28.9%
Finance Costs	10.7	3.6	12.1
Depreciation	17.1	12.3	19.6
PBT	75.9	(30.4)	131.8
Exceptional items (net)	-	-	-
Share of loss of associates	0.0	(0.8)	0.0
Tax Expenses	23.2	(7.3)	36.0
PAT	52.7	(23.9)	95.8
PAT Margin %	12.8%	(23.8%)	16.9%
Basic EPS (₹)	5.2	(2.1)	8.1



Proprietary POC Molecular Diagnostics Platform

- Truenat® brings real-time PCR capabilities closer to the patient
- Portable, battery-operated platform designed for decentralised testing
- Enables molecular diagnostics in resource constrained and remote settings



Speed & Accessibility

- Delivers molecular test results in **~60 minutes** for relevant Truenat® workflows
- Reduces dependence on centralised laboratories and sample transportation
- Enables faster diagnosis and treatment initiation at the point of care



Accuracy With Clinical & Regulatory Validation

- Real-time PCR-based technology designed to deliver laboratory-comparable diagnostic performance
- Validated across multiple disease applications
- WHO / ICMR and other regulatory & clinical validations strengthen credibility



One Platform | Multiple Diseases

- 43 assays covering 30 diseases as of March 2026
- Expanding menu across infectious diseases, women's health, oncology and other applications
- Growing assay portfolio increases the utility and potential utilisation of the installed base



Scalable & Recurring Business Model

- 12,500+ Truenat® devices installed across 90+ countries
- Installed instruments create an opportunity for repeat test-kit consumption
- Test kits contributed ~74% of product revenue in FY26, demonstrating the growing consumables-led revenue mix



Innovation-led Growth Engine

- Strong in-house R&D capabilities supported by 153 R&D professionals
- 207 registered patents underpin the technology and innovation ecosystem
- Continuous investment in new assays, applications and next-generation POC platforms expands the addressable opportunity

THANK YOU

For any investor queries, please contact

Molbio Diagnostics Limited

Indraneil Borkakoty - President – Corporate Strategy,
Mergers & Acquisitions and Investor Relations

indraneil.borkakoty@molbiodiagnostics.com

Adfactors PR - Investor Relations

Smit Shah / Anand Venugopal
+91 98707 89596 / +91 70218 52071

smit.shah@adfactorspr.com / anand.venugopal@adfactorspr.com